Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-15

Study Completion Date

2024-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess brain activity under Psilocybin in a cohort of people with fibromyalgia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia

NCT05128162

Fibromyalgia

COMPLETED PHASE2

The Impact of Psilocybin on Pain in Fibromyalgia Patients

NCT06368492

Fibromyalgia

RECRUITING NA

Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN

NCT06731335

Chronic Neuropathic Pain Pain Management

RECRUITING PHASE2

An fMRI Study Of Brain Response In Patients With Fibromyalgia

NCT00760474

Fibromyalgia

COMPLETED PHASE1

Psilocybin-facilitated Treatment for Chronic Pain

NCT05068791

Fibromyalgia, Primary

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This mechanistic (Non-CTIMP) study will utilise a within-subjects design to examine a candidate brain biomarker of increased plasticity under Psilocybin. Up to 25mg of Psilocybin will be administered under standardised conditions on two occasions, separated by four weeks with in-dosing EEG recordings.

The primary end-point will take place 8 weeks from the first dosing session after which patients will be remotely monitored monthly for 6 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fibromyalgia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fibromyalgia Cohort

\*As diagnosed by an appropriate medical professional according to the American College of Rheumatology(ACR) diagnostic criteria

Psilocybin

Intervention Type DRUG

Up to 25mg of Psilocybin on 2 occasions.

Therapeutic support

Intervention Type BEHAVIORAL

Psychological and physical therapeutic support

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Psilocybin

Up to 25mg of Psilocybin on 2 occasions.

Intervention Type DRUG

Therapeutic support

Psychological and physical therapeutic support

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Fibromyalgia lasting for more than 3 months, as diagnosed by an appropriate medical professional using the American College of Rheumatology diagnostic criteria.
* Over 18 years of age
* United Kingdom (UK) resident registered with a primary care medical practice
* Sufficiently competent in English with capacity to provide written informed consent
* Agreement for research team to contact primary and/or secondary care team over the course of the study
* No psychedelic use in the past 6 months

Exclusion Criteria

* Current or previously diagnosed psychotic disorder or bipolar disorder
* Immediate family member with a diagnosed psychotic disorder
* History of serious suicide attempts or presence of significant suicide/self-harm risk at screening
* Emotionally unstable personality, history of mania, or other psychiatric problem that the screening clinician feels may jeopardise the therapeutic alliance and/or safe exposure to psilocybin
* Currently using medication which could interact with psilocybin including anti-psychotics, mood stabilizers \& serotonergic antidepressants including selective serotonin reuptake inhibitors (SSRIs), SNRIs, and tricyclic antidepressants (TCAs)\*
* On waiting list for interventional treatment for pain (e.g. surgery or targeted injections)
* Actively enrolled on pain management programme over course of study or awaiting further investigations for pain
* Contraindications to EEG components of the study (e.g., epilepsy, migraine, focal scalp sensitivity)
* MRI contraindications (e.g. claustrophobia, metal implants)
* Physical co-morbidities that are unsuitable for the psychedelic component of the study (e.g., epilepsy, severe cardiovascular disease, insulin-dependent diabetes, hepatic or renal failure e.g., CrCl \< 30ml/min etc)
* Blood or needle phobia
* Positive pregnancy test at screening or during the study
* People who are breastfeeding
* Unable to engage with physical demands of dosing session (i.e. attend centre and remain in research facility for an extended period of time)
* Unable to access virtual meetings/phone for remote follow-ups
* Patients consuming more than 35 units of alcohol per week.
* Presence of new or un-investigated 'red flag' symptom indicating need for urgent investigation (e.g. upper motor neuron syndrome, gait ataxia, bladder or bowel dysfunction).
* Limited life expectancy (\<18 months) or rapidly deteriorating condition that may inhibit completion of the study (6 month remote follow up).
* Currently prescribed any of the following drugs: Antiepileptics, 5HT3-receptor antagonists, Aspirin, Coumarins, Cyproheptadine, Dabigatran, Dapoxetine, Duloxetine, Lithium, Methylphenidate, Methylthioninium, Metoclopramide, NSAIDs (should be avoided), Naratriptan, Pimozide, Rasagiline, Ritonavir, St John's Wort and Vortioxetine. Tramadol and Fentanyl will be avoided due to their serotonergic action, but all other opioids will not be grounds for exclusion.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No